Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2021/12/038418
CTRI/2021/12/038418
Not Yet Recruiting
N/A

TO EVALUATE THE SAFETY , EFFICACY AND PREDICTABILITY OF FEMTOSECOND LASER (LENSAR) ENABLED ARCUATE INCISIONS FOR THE CORRECTION OF PREOPERATIVE TOPOGRAPHIC ASTIGMATISM AT THE TIME OF CATARACT SURGERY

ENSAR0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
N/A
Intervention
Not specified
Conditions
Not specified
Sponsor
ENSAR
Status
Not Yet Recruiting
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
ENSAR

Eligibility Criteria

Inclusion Criteria

  • •CATARACT EYES WITH NO COMORBIDITIES
  • •ASTIGMATISM OF \-0\.75D TO \-2D
  • •UNILATERAL EYE

Exclusion Criteria

  • •CORNEAL ECTATIC CONDITIONS
  • •CORNEAL SCARS
  • •POST REFRACTIVE SURGERY
  • •RETINAL PATHOLOGIES

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
N/A
Evaluation of the safety, effectiveness and natural care approach of the Jauni phototherapy romper.icterusJaundice10019654
NL-OMON56682Erasmus MC, Universitair Medisch Centrum Rotterdam12
Not Yet Recruiting
Phase 2
Evaluation of the effect of microneedling with tranexamic acid in combination with hydroquinone formula in comparison with either alone in the treatment of melasma
IRCT20220122053789N1Iran University of Medical Sciences50
Not Yet Recruiting
Phase 3
Study of Tuberculosis resistant to treatmentHealth Condition 1: J988- Other specified respiratory disorders
CTRI/2021/03/032189International Union Against Tuberculosis and Lung Disease
Completed
Phase 1
An Open Label Study, to Evaluate Safety, Tolerability, and Efficacy in Male and Female with Androgenetic Alopecia Treated with HMI-115 over a 24-Week Treatment Period
ACTRN12622000680763Hope Medicine (Nanjing) Co., Ltd16
Active, Not Recruiting
N/A
EVALUATION OF THE EFFICACY, SAFETY AND TOLERABILITY OF THE CONCURRENT ADMINISTRATION OF CHF 4226 HFA pMDI AND EXTRAFINE BUDESONIDE HFA pMDI, BOTH GIVEN ONCE OR TWICE DAILY (2µg + 200µg qd or 1µg + 100µg bid) OVER AN 8-WEEK RANDOMIZED DOUBLE-BLIND TREATMENT PERIOD IN ADULT PATIENTS WITH MODERATE PERSISTENT ASTHMA AND PRESENTING WITH SYMPTOMS ON EXISTING INHALED CORTICOSTEROID THERAPY.Moderate persistent asthma sub optimally controlled on existing therapy.MedDRA version: 8Level: PTClassification code 10003553
EUCTR2006-000038-11-HUCHIESI Farmaceutici S.p.A304